泰国国家免疫规划中四种轮状病毒疫苗优先接种的成本效果与预算影响分析
泰国一项成本-效用分析采用传播动态模型,从社会视角评估四种WHO预认证轮状病毒疫苗(Rotarix、RotaTeq、ROTAVAC、ROTASIIL)引入国家免疫规划的cost-utility。结果显示不接种疫苗时轮状病毒年均发病312,118例,接种覆盖率>95%时年均避免144,299例;结论建议将轮状病毒疫苗纳入泰国国家疫苗接种规划。
要点
- 四种WHO预认证轮状病毒疫苗在泰国均成本节约,ROTASIIL最节约。
- 接种覆盖率>95%时年均避免144,299例轮状病毒病例。
核心结论
- 泰国应将轮状病毒疫苗纳入国家疫苗接种规划,四种WHO预认证疫苗均可减少政府医疗支出并带来健康收益。
研究设计与样本
- 成本-效用分析,采用传播动态模型,从社会视角模拟引入四种WHO预认证轮状病毒疫苗(Rotarix、RotaTeq、ROTAVAC、ROTASIIL)与不接种比较,对象为泰国<1岁儿童。
主要发现
- 不接种疫苗时模型预测轮状病毒年均发病312,118例。
- 接种覆盖率>95%时年均避免144,299例轮状病毒病例。
- 忽略间接效益时所有疫苗仍成本节约。
关键数值与推荐
- 成本效果阈值:增量成本效果比低于每QALY 5,110美元视为成本效果。
临床怎么用
- 泰国国家免疫规划可优先考虑ROTASIIL或ROTAVAC等成本节约更显著的疫苗,以在降低政府医疗支出的同时获得健康收益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rotavirus is a major cause of diarrhoea in children less than five years old in Thailand. Vaccination has been shown to be an effective intervention to prevent rotavirus infections but has yet to be enlisted in the national immunisation programme. This study aimed to assess the cost-utility of introducing rotavirus vaccines, taking all WHO-prequalified vaccines into consideration. METHODS: A cost-utility analysis was performed using a transmission dynamic model to estimate, from a societal perspective, the costs and outcomes of four WHO-prequalified rotavirus vaccines: Rotarix®, RotaTeq®, ROTAVAC® and ROTASIIL®. The model was used to simulate the impact of introducing the vaccines among children aged < 1 year and compare this with no rotavirus vaccination. The vaccination programme was considered to be cost-effective if the incremental cost-effectiveness ratio was less than a threshold of USD 5,110 per QALY gained. RESULTS: Overall, without the vaccine, the model predicted the average annual incidence of rotavirus to be 312,118 cases. With rotavirus vaccination at a coverage of more than 95%, the average number of rotavirus cases averted was estimated to be 144,299 per year. All rotavirus vaccines were cost-saving. ROTASIIL® was the most cost-saving option, followed by ROTAVAC®, Rotarix® and RotaTeq®, providing average cost-savings of USD 32, 31, 23 and 22 million per year, respectively, with 999 QALYs gained. All vaccines remained cost-saving with lower QALYs gained, even when ignoring indirect beneficial effects. The net saving to the healthcare system when implementing any one of these vaccines would be between USD 13 and 33 million per year. CONCLUSION: Rotavirus vaccines should be included in the national vaccination programme in Thailand. Implementing any one of these four WHO-prequalified vaccines would reduce government healthcare spending while yielding health benefits to the population.
引用
- Luangasanatip N, Mahikul W, Poovorawan K, et al. Cost-effectiveness and budget impact analyses for the prioritisation of the four available rotavirus vaccines in the national immunisation programme in Thailand. Vaccine. 2021. PMID: 33531197. doi:10.1016/j.vaccine.2021.01.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。